Company Overview of Interface Biologics, Inc.
Interface Biologics, Inc. develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. The company’s technology focuses on anti-thrombogenic additives and programmable combination drug delivery devices. It provides Endexo technology for blood contacting medical devices that addresses thrombosis problems; Epidel anti-infective polymers that allows for pharmaceuticals to be integrated directly into the medical device; and Kinesyx bioactive surface pacifying oligomers. The company was founded in 2001 and is headquartered in Toronto, Canada.
101 College Street
Toronto, ON M5G 1L7
Founded in 2001
Key Executives for Interface Biologics, Inc.
Interface Biologics, Inc. Key Developments
Similar Private Companies By Industry
|Osprey Pharmaceuticals Limited||Americas|
|Qubit Systems Inc.||Americas|
|SynX Pharma Inc.||Americas|
|Nanotech Systems Inc.||Americas|
|Receptor Therapeutics Inc.||Americas|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|NYC2012, Inc.||United States|
|Lawyers Committee for Civil Rights Under Law||United States|
|Rush University||United States|
|Citizens Budget Commission||United States|
Post a JobJobs
- San Francisco, CA | Investment Firm Providing Private and Institutional BrokeragePosted: Apr 07
- Gaithersburg, MD | MedimmunePosted: Apr 16
- San Mateo, CA |Posted: Apr 05
- New York | Shore ConsultantsPosted: Apr 14
Sponsored Financial Commentaries
To contact Interface Biologics, Inc., please visit www.interfacebiologics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.